Agenus Acquires Celexion Assets and Expands Its Antibody Discovery Platform

Agenus Acquires Celexion Assets and Expands Its Antibody Discovery Platform

April 8, 2015

SECANT® yeast display technology to provide speed and cost advantages

Combination with Agenus’ mammalian Retrocyte DisplayTM technology to result in a uniquely powerful antibody platform

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN) an immunology company developing innovative treatments for cancers and other diseases, today announced the acquisition of key antibody assets of Celexion, LLC, a privately held Cambridge, Mass. biotech company.

Acceleron Pharma Appoints Dr. Francois Nader as Chairman of its Board of Directors

Acceleron Pharma Appoints Dr. Francois Nader as Chairman of its Board of Directors

April 6, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced the appointment of Francois Nader, M.D., M.B.A, as the Chairman of its Board of Directors. Dr. Nader joined the Acceleron Board in December 2014.

BIND Therapeutics Announces Extension of Global Collaboration with Pfizer Inc. to Develop and Commercialize Multiple Accurins

BIND Therapeutics Announces Extension of Global Collaboration with Pfizer Inc. to Develop and Commercialize Multiple Accurins

April 2, 2015

- Progress made on preclinical research; Collaboration goals on track -

Flagship Ventures Closes $537 million for its Fifth Fund

Flagship Ventures Closes $537 million for its Fifth Fund

March 26, 2015

Up-sized Fund for Cambridge Venture Firm Focused on Healthcare and Sustainability

CAMBRIDGE, Mass., March 26, 2015 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, announced it has raised $537 million for Flagship Ventures Fund V, its largest fund since its founding in 2000. The new investment brings Flagship's aggregate funds under management to $1.4 billion.

Agios Pharmaceuticals Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency

Agios Pharmaceuticals Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency

March 24, 2015

 - PK deficiency is a severe and rare genetic disease with currently no approved or disease modifying treatments -

Pronutria Biosciences™ Appoints Dr. Christopher Wright as Senior Vice President and Chief Medical Officer

Pronutria Biosciences™ Appoints Dr. Christopher Wright as Senior Vice President and Chief Medical Officer

March 24, 2015

CAMBRIDGE, Mass., March 24, 2015 /PRNewswire/ -- Pronutria Biosciences™ Inc., a biotechnology company developing a new class of therapeutics to mediate amino acid biology, announced today the appointment of Dr. Christopher Wright as Senior Vice President and Chief Medical Officer. Dr. Wright will lead the company's global clinical development and medical affairs.

Syros Pharmaceuticals Announces New Research Published on Role of Cell Signaling Pathways in Gene Control

Syros Pharmaceuticals Announces New Research Published on Role of Cell Signaling Pathways in Gene Control

March 20, 2015

- Paper in Molecular Cell by Syros scientific founders validates approach to therapeutic gene control in cancers with signaling and transcriptional dependencies-

Investment from Flagship Ventures Brings Red Rock Biofuels Closer to Construction of its First Commercial Biofuel Refinery

Investment from Flagship Ventures Brings Red Rock Biofuels Closer to Construction of its First Commercial Biofuel Refinery

March 17, 2015

Fort Collins, CO – March 17, 2015 – Red Rock Biofuels LLC, a pioneer in renewable biofuels, today unveiled a strategic partnership with Flagship Ventures that sets the stage for the construction of its first commercial scale refinery in Lakeview, OR. As part of this partnership, Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, will invest in Red Rock, assume a seat on the Board of Directors and serve as a strategic advisor for future fundraising efforts.

Moderna Appoints Tal Zaks, Former Head of Sanofi Global Oncology, as Chief Medical Officer

Moderna Appoints Tal Zaks, Former Head of Sanofi Global Oncology, as Chief Medical Officer

March 16, 2015

CAMBRIDGE, Mass., March 16, 2015 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™ across a range of therapeutic applications, announced today that Tal Zaks, M.D., Ph.D., will join Moderna’s executive leadership team as chief medical officer, effective March 16.

Prior to joining Moderna, Dr. Zaks was senior vice president and head of Global Oncology at Sanofi, where he was responsible for all aspects of oncology drug discovery, development and commercialization.

Concert Pharmaceuticals Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor for Cystic Fibrosis

Concert Pharmaceuticals Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor for Cystic Fibrosis

March 12, 2015

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that is has initiated its Phase 1 clinical program for deuterium-modified ivacaftor, a novel, potentially disease-modifying treatment for cystic fibrosis. Ivacaftor is commercially available under the name Kalydeco®. The first Phase 1 trial will be a crossover study to compare two proprietary deuterium-modified compounds in order to select one for further clinical evaluation.